Overview of Эпленор

What is Eplenor?

Eplenor is a brand name medication containing the active ingredient eplerenone, an established drug classified as a selective aldosterone antagonist or a potassium-sparing diuretic. This compound is specifically designed to manage conditions influenced by the Renin-Angiotensin-Aldosterone System (RAAS), a hormonal pathway that controls fluid balance, salt retention, and blood pressure.

Eplenor is supplied in oral tablet form and is available by prescription only (Rx). The drug is primarily used in the management of high blood pressure (hypertension) and to improve long-term outcomes and survival for patients with heart failure following a myocardial infarction (heart attack).

Clinical Features and Differentiation

Eplerenone is clinically recognized for its high selectivity in blocking the mineralocorticoid receptor, a key feature that differentiates it from older medications like spironolactone. This precise mechanism of action is characterized in pharmacological literature. This selectivity may contribute to a potentially lower incidence of certain hormone-related side effects, such as gynecomastia (breast enlargement in men).

As a treatment example, Eplenor may be prescribed as part of a comprehensive regimen for a patient with established heart failure and reduced ejection fraction to help mitigate the damaging effects of chronic aldosterone activation on the heart muscle. In the United States, the reference listed drug for this active ingredient is Inspra. Its role in cardiovascular risk reduction underscores its therapeutic importance.

What side effects are possible with Эпленор?

Possible Side Effects and Safety Information

The official safety profile for Eplenor (eplerenone) is primarily defined by the risk of electrolyte imbalance, particularly hyperkalemia (high potassium in the blood), which is consistently documented in regulatory labels as the most significant safety concern. This risk is managed through patient selection and monitoring, with the majority of hyperkalemia cases observed within the first three months of treatment initiation, as noted in clinical trial data.

Adverse Reaction Classification

Side effects are categorized by frequency, based on reports from clinical trials submitted to health authorities like the FDA and EMA. Common adverse reactions (1/100 to < 1/10) often involve laboratory changes and general systemic effects, while serious reactions are less frequent but clinically critical.

Common Effects: Frequently documented adverse reactions include dizziness, increased blood creatinine (a laboratory finding), cough, diarrhea, and fatigue. These reactions are classified within System-Organ Classes such as Nervous System Disorders and Gastrointestinal Disorders.
Serious Adverse Reactions: The primary serious risk is severe hyperkalemia, which can lead to life-threatening cardiac arrhythmias. The risk of acute kidney injury and renal failure is also documented, particularly in susceptible patients.

Population-Specific Safety Considerations

Official regulatory documents establish constraints for use in specific populations due to heightened risk:

Renal and Hepatic Impairment: Eplenor is contraindicated in patients with severe renal impairment (e.g., creatinine clearance < 30 mL/min) and severe hepatic impairment due to the increased risk of adverse effects.
Older Adults (Age 65): This group is noted to have an increased risk of hyperkalemia and requires close serum potassium monitoring, as explicitly stated in the prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for eplerenone overdosage identifies the most likely clinical manifestations as the severe exaggeration of the drug's intended effects. The primary documented presentations are hypotension (severely low blood pressure) and hyperkalemia (dangerously high potassium levels in the blood). Associated signs of hyperkalemia can include muscle weakness, confusion, nausea, and vomiting.

Severe Risks and Emergency Response

The most severe risk documented is that unmanaged hyperkalemia can lead to serious, sometimes fatal, arrhythmias, classifying the overdose as potentially life-threatening. Therefore, regulatory authorities stress that immediate medical attention is required upon suspicion of overdose. Urgent contact with a Poison Control center or an emergency room is mandated.

Immediate Emergency Action: Emergency services must be called immediately if the affected individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Supportive Management

Treatment is strictly symptomatic and supportive, with primary efforts focused on the correction of hyperkalemia and management of hypotension. No specific antidote is known for eplerenone. Procedural guidance states that eplerenone is not removed by hemodialysis. Population-specific notes indicate that the elderly and individuals with impaired renal function have a heightened vulnerability to severe hyperkalemia in overdose situations.

Therapeutic Uses of Эпленор

What Эпленор Treats: Main Uses and Benefits

Eplenone is generally used to provide supportive management across major cardiovascular domains, focusing on therapeutic support during periods of physiological strain and easing symptom burden associated with chronic heart conditions. The medication is indicated for the management of hypertension and is relevant for supportive management in certain patients with heart failure following a heart attack.

Easing Fluid Retention and Heart Failure Symptoms

The medication is commonly used across conditions where symptoms related to systemic imbalance and volume overload create noticeable physiological strain, particularly in patients with established heart failure. Eplenone is used to address symptom clusters that may become intense or disruptive due to volume imbalance, such as edema (swelling) and shortness of breath. This supportive therapeutic benefit helps ease the overall symptom burden and contributes to improved day-to-day comfort during periods of heightened symptoms.

Quick Fact: Supportive Management for Volume Overload This medication plays a role in managing symptoms like swelling and shortness of breath associated with fluid retention in chronic heart conditions.

Eligibility and Restrictions for Use

Eplerenone is a prescription medication primarily used to treat high blood pressure (hypertension) and to improve survival in patients with heart failure following a heart attack.

Who Can Use Eplerenone

Most adults who have been diagnosed with these conditions may be candidates for treatment with eplerenone. It is often used in conjunction with other medications.

Who Cannot Use Eplerenone (Contraindications)

Eplerenone is not suitable for everyone and is generally contraindicated in patients with the following conditions, primarily due to the increased risk of developing high potassium levels (hyperkalemia):

Condition/Criteria	Specific Concern
High Serum Potassium	Starting with potassium levels >5.5 mEq/L
Severe Kidney Impairment	Creatinine clearance le 30 mL/min
Type 2 Diabetes (for Hypertension)	With microalbuminuria (increased protein in urine)
Concomitant Strong CYP3A Inhibitors	Certain antifungals (e.g., ketoconazole, itraconazole) or antivirals (e.g., ritonavir)
Concomitant Potassium-Sparing Diuretics	(e.g., spironolactone, amiloride) or potassium supplements

Patients should also inform their healthcare provider if they have an allergy to eplerenone, liver disease, or are pregnant or breastfeeding. Regular blood tests to monitor potassium and kidney function are essential for all patients taking this medication.

What should I know about interactions with other medicines?

Eplerenone Interactions with Other Medicines and Products

Interactions with Eplerenone are primarily classified based on effects on drug exposure and potassium levels, as documented in regulatory information.

Contraindicated Combinations

The co-administration of Eplerenone is strictly contraindicated with the following due to significant risk of adverse effects, primarily severe hyperkalemia or excessive exposure increase:

Strong CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole).
Potassium Supplements.
Potassium-Sparing Diuretics (e.g., spironolactone, triamterene, amiloride).

Pharmacokinetic (PK) and Pharmacodynamic (PD) Interactions

Interaction Type	Interacting Agents (Examples)	Resulting Constraint
PK via CYP3A4	Moderate CYP3A4 Inhibitors (e.g., fluconazole, erythromycin)	Require reduction of the Eplerenone dose.
PK via CYP3A4	CYP3A4 Inducers (e.g., rifampicin, St. John's wort)	Decrease Eplerenone concentration; combination should be avoided.
PD (Hyperkalemia)	ACE Inhibitors or ARBs	Requires careful monitoring of serum potassium levels.
Non-Drug Substance	Grapefruit Juice	Increases Eplerenone exposure; co-consumption is restricted.

Population-Specific Notes

Eplerenone use is contraindicated in patients with severe renal impairment ( CrCl leq 30 mL/min) and severe hepatic impairment (Child-Pugh Class C) due to documented increased risk of hyperkalemia and lack of evaluation, respectively.

Mechanism of Action

Эпленор is a bisphosphonate derivative that targets and binds selectively to hydroxyapatite crystals present in the mineralized bone matrix. This selective affinity results in accumulation at sites of active bone remodeling. Upon incorporation into the bone structure, the molecule is internalized by osteoclasts—the cells responsible for bone resorption—during their activation cycle. Within the osteoclast, Эпленор acts as an inhibitor of the enzyme farnesyl pyrophosphate synthase (FPPS), a key component in the mevalonate pathway. Inhibition of FPPS disrupts the prenylation of small guanosine triphosphate (GTP)-binding proteins, leading to cytoskeletal changes and impaired osteoclast function. The subsequent loss of ruffled border integrity and induction of osteoclast apoptosis reduces the number and activity of functional osteoclasts, consequently decreasing the overall rate of bone resorption and modulating the bone remodeling cycle.

Dosage and Administration Information

Eplerenone is taken orally as a tablet and may be administered with or without food. It is typically taken once or twice daily, and adhering to the same time each day is recommended to maintain the dosing schedule.

Official Dosing and Monitoring

Administration requires careful and mandatory monitoring of serum potassium levels, as this guides the starting dose, subsequent adjustments, and continued therapy. Serum potassium must be measured before initiation, within the first week, and one month after starting treatment or after any dose adjustment.

Clinical Context	Recommended Starting Dose	Titration/Maximum Dose
Heart Failure Post-Myocardial Infarction	25 mg once daily	Titrate to 50 mg once daily within four weeks, based on serum potassium.
Hypertension	50 mg once daily	Increase to 50 mg twice daily if blood pressure is inadequately controlled. Doses over 100 mg/day are not recommended.

Dose Adjustment based on Potassium Level (Post-MI Heart Failure):

Serum Potassium (mEq/L)	Action
5.0–5.4	Maintain dose.
5.5–5.9	Decrease dose.
≥ 6.0	Withhold Eplerenone; restart at a lower dose when potassium falls below 5.5 mEq/L.

If a dose is missed, take it as soon as you remember that day. If it is almost time for the next scheduled dose, skip the missed one and continue with the regular schedule. Do not take a double dose to compensate for the missed one. No starting dose adjustment is generally required for elderly patients, but monitoring for hyperkalemia is necessary due to potential age-related decline in renal function.

Recent Clinical Evidence

Research evidence / Overview of studies for Эпленор

Evidence for Patients with Heart Failure Following a Heart Attack

Research exploring Эпленор (eplerenone) was evaluated in stable adult patients who had experienced a heart attack and had resulting heart muscle weakness. These studies were conducted as large-scale, multinational Randomized Controlled Trials (RCTs). Researchers specifically examined outcomes related to survival (all-cause mortality) and the rate of cardiovascular (CV) hospitalizations, tracking phases of heightened symptom activity.

The main findings describe patterns observed in the studies where the composite endpoint showed a lower event rate in the study group compared to the placebo group. Research tracked the frequency of all-cause death and CV death, and studies monitored different rates of occurrence in the observed populations during the study period. These studies monitored patients who were already receiving the recommended standard medical therapy for their condition.

The primary clinical trial had an intermediate follow-up duration, with patients monitored over defined time intervals of about 16 months. Because the data applied only to the populations studied, the long-term observation periods beyond the initial trial duration are not fully characterized by the initial controlled study.

Evidence for Chronic Heart Failure with Mild Symptoms

For patients diagnosed with long-term (chronic) heart failure and mild symptoms (NYHA Class II), studies focused on those with reduced heart pumping ability. These were also large, placebo-controlled Randomized Controlled Trials (RCTs) designed to track major health events.

Research examined outcomes such as the composite endpoint of Cardiovascular death or first hospitalization for heart failure. The findings describe patterns observed in the studies where the composite endpoint showed a lower event rate in the study group. The studies tracked participants who were already on recommended standard medical treatments. In one key trial, the study was stopped earlier than planned because the findings met pre-specified criteria during an interim review.

Because the key study was terminated early, the follow-up durations were limited for the maximum potential observation period. Therefore, the full scope of very long-term results and events, particularly beyond the initial median follow-up of about 21 months, are not fully established by the completed RCT.

Frequently Asked Questions (FAQ)

Common questions about Эпленор (FAQ)

Q: Is it normal to feel tired when first starting Эпленор?

A: Studies and official information indicate that excessive tiredness and fatigue have been reported as common side effects of Eplerenone. This general feeling of being tired may occur, particularly when first starting the medication. If you experience severe or persistent tiredness, it is important to discuss it with a healthcare professional.

Q: Are there any foods or drinks I should avoid while taking Эпленор?

A: Regulatory documents state that you should avoid consuming grapefruit and drinking grapefruit juice while taking Eplenor. Grapefruit products can increase the amount of Eplenone in your body, potentially raising the risk of side effects. Regulatory documents do not list other specific food or beverage contraindications.

Q: What happens if I drink alcohol while on Эпленор?

A: Official product information suggests that consuming alcohol while taking Eplenor may enhance the medication's effect of lowering blood pressure. This enhanced effect could potentially lead to symptoms like dizziness or lightheadedness. Any use of alcohol should be discussed with a healthcare provider.

Q: Can Эпленор be taken with a multivitamin?

A: Regulatory information indicates that potassium supplements must not be taken while you are on Eplenor due to a significant risk of hyperkalemia (dangerously high potassium levels). You should check the ingredients of any multivitamin or supplement to ensure it does not contain added potassium. All supplements should be reviewed by a healthcare provider before use.

Q: Does Эпленор affect sleep?

A: While not listed as a common side effect, some post-marketing reports for Eplenone have included instances of difficulty sleeping (insomnia). If you experience significant sleep disruption, consider reporting it to a healthcare professional.

Q: Does Эпленор help with swelling or fluid retention?

A: Eplenor is classified as a potassium-sparing diuretic. Its mechanism of action helps the body excrete excess sodium and water by blocking the hormone aldosterone. This mechanism is key to managing fluid-related symptoms, such as swelling or fluid retention, often associated with heart conditions.

Q: Why is Эпленор sometimes prescribed after a heart attack?

A: The drug is officially indicated and prescribed after a heart attack (acute myocardial infarction) for stable patients who also have reduced heart function. According to clinical trial evidence, the medication is intended to help improve long-term survival and clinical outcomes for these specific patients.

Q: Is Эпленор a steroid?

A: Eplenone is chemically a steroidal structure derived from pregnene. Its function is to block the mineralocorticoid receptor, which normally binds to the steroid hormone aldosterone, regulating salt and fluid balance. It does not act like the steroids used for inflammation.

Q: Can Эпленор cause changes in blood sugar?

A: Official safety documents do not list changes in blood sugar as an expected adverse reaction. However, Eplenor is contraindicated in certain patients with Type 2 Diabetes and specific signs of kidney issues, due to a heightened risk of high potassium levels in that group. Following the monitoring schedule provided by your prescriber is important.

Q: Does taking Эпленор require any lifestyle changes?

A: Taking Eplenor requires attention to certain dietary habits. Patients are generally advised to avoid consuming grapefruit products and may be instructed to monitor their diet for potassium intake. Discussing your diet and medication regimen with your provider is recommended for safe management.

Q: Are headaches a common side effect of Эпленор?

A: Headache is listed in regulatory sources as a potential side effect that may occur while taking this medication. If you experience frequent or severe headaches, especially when starting treatment, it is important to inform your healthcare professional.

Q: Does Эпленор interact with over-the-counter cold and flu medicine?

A: Eplenor is known to interact with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, which are common ingredients in many over-the-counter cold and flu medicines. Combining them can increase the risk of high potassium and kidney problems. It is important to check product labels and consult with a healthcare provider before combining Eplenor with any over-the-counter medications.

Q: Does Эпленор make you urinate more often?

A: Yes, Eplenor functions as a potassium-sparing diuretic. Its mechanism of action helps the body excrete more sodium and water through the kidneys, and this can result in an increase in the frequency and volume of urination.

Q: How does Эпленор affect the body's hormones?

A: Eplenor works by selectively blocking the action of the hormone aldosterone, which is part of the body’s system that regulates fluid, salt balance, and blood pressure. By blocking this hormone at its receptor, it helps prevent the damaging effects of excessive aldosterone activity.

Q: Can children or teenagers take Эпленор?

A: According to the official product information, the safety and effectiveness of Eplenor have not been established for use in pediatric patients (under 18 years of age). Therefore, it is typically not recommended for this age group.

Q: How long does it take for Эпленор to start working?

A: When treating high blood pressure, the full therapeutic effect of Eplenor is typically observed within four weeks of starting treatment. For heart conditions, while the drug is working immediately, clinical benefits are generally monitored over the long term.

Q: Can Эпленор interact with common pain relievers?

A: Yes, Eplenor interacts with common pain relievers known as Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), which include drugs like ibuprofen. This combination increases the risk of high potassium levels (hyperkalemia) and potential kidney problems. The combination may require careful monitoring by a healthcare provider.

How should Эпленор be stored and disposed of?

Storage and Disposal Information

Storage Requirements

Eplerenone tablets must be stored at Controlled Room Temperature, specifically between 20 to 25 C (68 to 77 F). Brief excursions are allowed between 15 to 30 C (59 to 86 F). Keep the medication in the container it came in, with the cap tightly closed, to protect it from excess heat and moisture. It is essential to store this medication in a safe location, high up and away, and out of the sight and reach of children.

Disposal Instructions

When disposing of unused or expired Eplerenone, follow all applicable regulatory guidelines. The preferred disposal method is through a drug take-back program (e.g., mail-back or drop-off sites) if one is available. If a take-back program is not readily accessible, and the drug is not on the FDA flush list, mix the tablets with an undesirable substance (such as dirt or cat litter) in a sealed container, and discard the container in the household trash. Do not flush this medication down the toilet.

Эпленор